多替阿巴拉米片什么时候上市的？

On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-pill combination preparation (Triumeq) based on the new generation integrase inhibitor dolutegravir (DTG) for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. Dolutegravir is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. The drug is based on the treatment plan of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. It was approved by the FDA on August 27, 2014.

Dolutegra is the best-selling AIDS drug in the world in the past five years, and it is also an important player of GSK China in the field of AIDS in recent years. Since its approval for launch in 2014, the sales volume of Dolutegra abalami tablets has increased by leaps and bounds. In 2016, it ranked first in the global AIDS drug rankings, becoming GSK's best-performing business segment. Regarding pricing, Dolutegra abalami tablets are currently priced at $2,880/month in the Chinese market. In an interview with a reporter from E Drug Manager, Xu Ding, vice president of government affairs and communications at GSK, said: The price of Dolutea Paramid Tablets in China is the lowest in neighboring countries and regions. Next, GSK will actively coordinate and communicate with relevant departments to promote Dolutegra Abalamid Tablets to enter China's free AIDS drug list as soon as possible, benefiting more patient groups.

The Dolutegra abalami tablets (Inbec) launched this time are China's first complete single-tablet three-in-one preparation with DTG as the core, filling the gap in single-piece compound preparations. GSK has previously had a DTG drug on the market, with the trade name Tevicay. It was launched in the United States in 2013, but it needs to be used in combination with other drugs. Dolutegra abalami tablets are a complete single-tablet three-in-one preparation with DTG as the core. It can be taken once a day, one tablet at a time, without considering factors such as food, environment, location, etc. AIDS is generally recognized as a chronic disease. For chronic diseases, patient compliance is particularly important. Taking one pill once a day reduces the frequency and dosage of medication and significantly enhances patient compliance.